Pre-operative tranexamic acid reduces blood loss in ovarian cancer patients
As reported in ACTA Obstetricaet Gynecologica, a single pre-operative dose of tranexamic acid (15 mg/kg) significantly reduced blood loss (520 cc vs 730 cc) and the transfusion rate (30% vs. 44%) in ovarian cancer patients (n=100) undergoing radical debulking.
Atypical glandular cells associated with increased risk of extrauterine disease
As reported in the International Journal of Gynecologic Cancer, abnormal cervical cytology (atypical glandular cells [AGC] or malignant cells [MC]) on pre-operative cervical cytology predicts extrauterine disease (OR=4.78) and high intermediate risk disease (OR=8.41) in patients with endometrial adenocarcinoma (n=563). In patients with an elevated CA-125 level, the OR for extrauterine and high intermediate risk disease was 13.3 and 5.83, respectively.
Endometrial and ovarian cancer risk increased in PCOS
Based on a meta-analysis reported in Human Reproduction Update, women with polycystic ovarian syndrome [PCOS] (n=919; 11 studies) < 54 years of age, are at increased risk for endometrial (HR = 4.05) and ovarian cancer (HR = 2.52), but not breast cancer (HR = 0.78).